Evidence map›Paper›PMID 31360433›Full record

ReviewTherapeutic advances in drug safety2019

Development of a pharmacovigilance system in a resource-limited country: the experience of the Democratic Republic of Congo.

Didier Nzolo, Andrea Kuemmerle, Yves Lula, Nsengi Ntamabyaliro, Aline Engo, Bibiche Mvete, Jerry Liwono, Mariano Lusakibanza, Gauthier Mesia, Christian Burri and 2 more

Abstract readReview
In one paragraph

Review in Therapeutic advances in drug safety, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Didier NzoloUnit of Clinical Pharmacology and pharmacovigilance, University of Kinshasa, Kinshasa, 11, Democratic Republic of Congo.ORCID https://orcid.org/0000-0002-1297-9581
Andrea KuemmerleSwiss Tropical and Public Health Institute, Basel, Switzerland.
Yves LulaUnit of Clinical Pharmacology and pharmacovigilance, University of Kinshasa, Kinshasa, Democratic Republic of Congo.
Nsengi NtamabyaliroUnit of Clinical Pharmacology and pharmacovigilance, University of Kinshasa, Kinshasa, Democratic Republic of Congo.
Aline EngoUnit of Clinical Pharmacology and pharmacovigilance, University of Kinshasa, Kinshasa, Democratic Republic of Congo.
Bibiche MveteUnit of Clinical Pharmacology and pharmacovigilance, University of Kinshasa, Kinshasa, Democratic Republic of Congo.
Jerry LiwonoUnit of Clinical Pharmacology and pharmacovigilance, University of Kinshasa, Kinshasa, Democratic Republic of Congo.
Mariano LusakibanzaUnit of Clinical Pharmacology and pharmacovigilance, University of Kinshasa, Kinshasa, Democratic Republic of Congo.
Gauthier MesiaUnit of Clinical Pharmacology and pharmacovigilance, University of Kinshasa, Kinshasa, Democratic Republic of Congo.
Christian BurriSwiss Tropical and Public Health Institute, Basel, Switzerland.
Samuel MampunzaUnit of Clinical Pharmacology and pharmacovigilance, University of Kinshasa, Kinshasa, Democratic Republic of Congo.
Gaston TonaUnit of Clinical Pharmacology and pharmacovigilance, University of Kinshasa, Kinshasa, Democratic Republic of Congo.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Implementation of pharmacovigilance (PV) systems in resource-limited countries is a real endeavor. Despite country- and continent-specific challenges, the Democratic Republic of the Congo (DRC) has been able to develop one of the most active PV systems in the sub-Saharan Africa. The World Health Organization (WHO) regional Office identified the DRC experience to set up a PV system for antimalarial drugs safety monitoring as a 'best practice' that needed to be documented in order to help DRC improve its PV system and to be scaled up in other African countries. In response to the WHO request, a best practices and bottlenecks analysis was conducted in 2015. This analysis was updated in 2018 in the light of the minimum requirements of the WHO to set up a PV system taking into account other guidance for PV systems. The following themes were retained for analysis: (1) creation of the national PV center; (2) implementation of PV in the health system; (3) data collection and analysis; (4) collaboration with public health programs; (5) collaboration with the National Regulatory Authority. Lessons learnt from the DRC experience show that it is possible to implement PV systems in order to promote patients' safety in resource limited sub-Saharan African countries with no guaranteed funding. The ability of national PV centers to collaborate with Public health stakeholders, including public health authorities at all levels as well as public health programs, and to use existing health information systems are considered the main key to success and may substantially reduce the cost of PV activities.

Indexed as

Africabest practicesDemocratic Republic of Congolow- and middle-income countrypharmacovigilanceresource-limited country

Identifiers

PMID31360433
PMCPMC6637826

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.